CAJ | 학술논문

目的：比较头颈部鳞状细胞癌（SCCHN）治疗中TNP（紫杉醇＋奈达铂＋替加氟）与PF（氟尿嘧啶＋顺铂）组的近期疗效以及不良反应。方法分析2009年—2014年在襄阳市中心医院接受治疗的SCCHN患者的临床资料。根据治疗方案将患者划分为PF组和TNP组。比较两组患者的一般资料、临床特征、治疗疗效以及治疗不良反应。结果本研究纳入患者54例，其中TNP组和PF组各27例，两组患者的临床资料并无统计学差异（P＞0．05）；两组患者的肿瘤部位、临床分期及分化程度均无统计学差异（P＞0．05）；TNP组患者的治疗疗效优于PF组，差异具有统计学意义（χ2＝7．864，P＝0．048）；TNP组患者的胃肠道反应发生率显著低于PF组（χ2＝4．854，P＝0．028），其余不良反应均无统计学差异（P均＞0．05）。结论在SCCHN治疗中，TNP方案疗效优于PF方案，且治疗过程中的胃肠道不良反应发生率更低。
목적：비교두경부린상세포암（SCCHN）치료중TNP（자삼순＋내체박＋체가불）여PF（불뇨밀정＋순박）조적근기료효이급불량반응。방법분석2009년—2014년재양양시중심의원접수치료적SCCHN환자적림상자료。근거치료방안장환자화분위PF조화TNP조。비교량조환자적일반자료、림상특정、치료료효이급치료불량반응。결과본연구납입환자54례，기중TNP조화PF조각27례，량조환자적림상자료병무통계학차이（P＞0．05）；량조환자적종류부위、림상분기급분화정도균무통계학차이（P＞0．05）；TNP조환자적치료료효우우PF조，차이구유통계학의의（χ2＝7．864，P＝0．048）；TNP조환자적위장도반응발생솔현저저우PF조（χ2＝4．854，P＝0．028），기여불량반응균무통계학차이（P균＞0．05）。결론재SCCHN치료중，TNP방안료효우우PF방안，차치료과정중적위장도불량반응발생솔경저。
Objective Our retrospective study is aimed to compare the effect and the adverse reaction of TNP(paclitaxel liposome +nedaplatin +tegafur)and PF(fluorouracil +cisplatin)in the treatment of head and neck squamous cell carcinoma(SCCHN).Methods Clinical data of patients with SCCHN received treatment at our hospital from 2009 to 2014 was retrospectively analyzed .Patients were divided into PF group and TNP group according to the treatment prescription .The general data,clinical features,treatment and the adverse reactions of the two groups were compared .Results A total of 54 patients was retrospective analyzed ,including 27 patients in TNP group and 27 in PF group.There was no significant differences in clinical data between the two groups .There was no significant differences in the location of the tumor ,clinical stage and differentiation degree between the two groups.The curative effect of TNP group was significantly ameliorated than the PF group .The incidence of gastro-intestinal reaction in TNP group was obviously lower than in PF group .There was no significant differences in the other adverse reactions .Conclusion In the treatment of SCCHN , TNP regimen is more effective than PF regi-men,and the incidence of gastrointestinal adverse reaction during the treatment is lower .